None listed
Conditions
Brief summary
This study aims to explore whether participating in exercise during adjuvant chemotherapy can improve treatment tolerance and more specifically chemotherapy completion rates. Who is it for? You may be eligible for this study if you are aged 18 years or older, have been diagnosed with a stage I-III solid tumour and are scheduled to receive chemotherapy. Study details Participants will be offered twice-weekly supervised small group exercise sessions for the duration of their adjuvant chemotherapy, or for a maximum of 8 months. Exercise sessions will last approximately 60 minutes and involve a combination of aerobic, resistance, and balance exercises. Participants will also be encouraged to engage in additional aerobic exercises at home with the goal of reaching a total of at least 150 minutes of moderate to vigorous intensity aerobic exercise each week. Data on chemotherapy completion, physical and mental wellbeing will be collected before, during and after the intervention. It is hoped that information from this study will help determine whether participating in exercise during adjuvant chemotherapy has a beneficial effect on chemotherapy completion rates and physical and mental wellbeing in people diagnosed with cancer.
Interventions
Exercise intervention Participants will be offered two supervised exercise sessions/week throughout the course of their chemotherapy treatment plus 2 weeks (max. 8 months). The exercise sessions will be conducted in small groups under the direct supervision of an exercise physiologist (EP) and last approximately 60 minutes. Prior to commencing the program, each participant will receive a consultation with the EP (as part of their baseline assessment) in order to individualise the exercise prescription to their specific needs according to their cancer and general health history, and physical abilities. The individualised prescription (i.e. specific exercise selection, intensity and progression) will be designed in accordance with national and international guidelines for best practice in exercise prescription for people with cancer, involving a combination of aerobic, resistance, and balance exercise (American College of Sports Medicine, Clinical Oncology Society of Australia, Exercise and Sports Science Australia). Specifically, the aerobic exercise component will include 20 to 25 minutes of moderate intensity continuous to vigorous intensity cardiovascular exercise (~60-85% of estimated maximum heart rate) using a variety of modes such as walking or jogging on a treadmill or cycling on a stationary ergometer. Participants will be encouraged to undertake additional home-based aerobic exercise with the goal of achieving a total of at least 150 minutes of moderate to vigorous intensity aerobic exercise each week. The resistance exercise component will last approximately 25 minutes and involve 4-6 exercises that target the major upper and lower body muscle groups (e.g. chest press, leg press). Intensity will be manipulated from 6-12 repetition maximum (RM; i.e. the maximal weight that can be lifted 6 to 12 times which is equivalent to ~60-85% of 1RM) using 2-3 sets per exercise. Exercise prescription will be progressive and modified according to individual response. The aim will be for patients to exercise with an intensity that they perceive as being “somewhat hard” to “hard” (rating between 12 and 15 on The Borg Rating of Perceived Exertion Scale). The balance exercise component will last 5 to 10 minutes, include exercises that involve a variety of different stances (e.g., single leg, tandem balance) and will be progressed by including more challenging tasks. Exercise session frequency (i.e. attendance) as well as adherence to supervised aerobic and resistance exercise (i.e. prescribed vs completed training volume) will be recorded. This includes early session terminations, exercise or dose (e.g. number of sets, repetitions, or load reductions) modifications but also dose escalations. Reasons for any missed exercise sessions (e.g. conflicting appointment) and changes in exercise prescription (e.g. fatigue) will be documented by study team members.
Sponsors
Study design
Eligibility
Inclusion criteria
1) Diagnosed with a solid tumour (stages I-III), 2) Scheduled for first-line adjuvant chemotherapy with curative intent, 3) Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2, 4) Greater than or equal to 18 years of age.
Exclusion criteria
1) Other actively treated cancer (expect for non-melanoma skin cancer), 2) Having received chemotherapy previously, 3) Any medical condition that could place the participant at unreasonable risk of injury or illness caused by the exercise testing or training; 4) Pregnant 5) Unable to read, speak or understand English (and no interpreter).